Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol 2015; 16: 1617-29.GayFOlivaSPetrucciMTConticelloCCatalanoLCorradiniPChemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trialLancet Oncol20151616172910.1016/S1470-2045(15)00389-7Search in Google Scholar
Lonial S, Boise LH, Kaufman J. How I treat high risk myeloma. Blood 2015; 126: 1536-43.LonialSBoiseLHKaufmanJHow I treat high risk myelomaBlood201512615364310.1182/blood-2015-06-653261Search in Google Scholar
Palumbo A, Cavallo F, Gay F, Raimondo F, Yehudda DB, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371: 895-905.PalumboACavalloFGayFRaimondoFYehuddaDBPetrucciMTAutologous transplantation and maintenance therapy in multiple myelomaN Engl J Med201437189590510.1056/NEJMoa1402888Search in Google Scholar
Zver S, Mlakar U. Slovenske smernice za obravnavo diseminiranega plazmocitoma 2015. Zdr Vestn 2015; 84: 335-51.ZverSMlakarUSlovenske smernice za obravnavo diseminiranega plazmocitoma 2015Zdr Vestn2015843355110.6016/ZdravVestn.1343Search in Google Scholar
Mohty M, Harousseau JL. Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. Haematologica 2014; 99: 408-16.MohtyMHarousseauJLTreatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersHaematologica2014994081610.3324/haematol.2013.096149Search in Google Scholar
Silvennoinen R, Anttila P, Säily M, Lundan T, Heiskanen J, Siitonen TM, et al. A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. Bone Marrow Transplant 2015; 51: 372-6.SilvennoinenRAnttilaPSäilyMLundanTHeiskanenJSiitonenTMA randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myelomaBone Marrow Transplant201551372610.1038/bmt.2015.236Search in Google Scholar
Kuan JW, Su AT, Wong SP, Sim X, Toh SG, Ong TC, et al. A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization. Transfus Apher Sci 2015; 53: 196-204.KuanJWSuATWongSPSimXTohSGOngTCA randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilizationTransfus Apher Sci20155319620410.1016/j.transci.2015.03.017Search in Google Scholar
Kim MG, Han N, Lee E-K, Kim T. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and metaanalysis. Bone Marrow Transplant 2015; 50: 523-30.KimMGHanNLeeE-KKimTPegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and metaanalysisBone Marrow Transplant2015505233010.1038/bmt.2014.297Search in Google Scholar
Gertz M, Kumar S, Lacy M, Dispenzieri A, Hayman S, Buadi F, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009; 43: 619-25.GertzMKumarSLacyMDispenzieriAHaymanSBuadiFComparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myelomaBone Marrow Transplant2009436192510.1038/bmt.2008.369Search in Google Scholar
Hamadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, et al. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol Blood Marrow Transplant 2012; 18: 1128-35.HamadaniMKochuparambilSTOsmanSCumpstonALeadmonSBunnerPIntermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapiesBiol Blood Marrow Transplant20121811283510.1016/j.bbmt.2012.01.005Search in Google Scholar
Condomines M, Quittet P, Lu Z-Y, Nadal L, Latry P, Lopez E, et al. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J Immunol 2006; 176: 6631-39.CondominesMQuittetPLuZ-YNadalLLatryPLopezEFunctional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factorJ Immunol200617666313910.4049/jimmunol.176.11.6631Search in Google Scholar
Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant 2008; 14: 807-16.PorrataLFInwardsDJAnsellSMMicallefINJohnstonPBGastineauDAEarly lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective studyBiol Blood Marrow Transplant2008148071610.1016/j.bbmt.2008.04.013Search in Google Scholar
Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579-85.PorrataLFGertzMAInwardsDJLitzowMRLacyMQTefferiAEarly lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphomaBlood2001985798510.1182/blood.V98.3.579Search in Google Scholar
Kim H, Sohn H-J, Kim S, Lee JS, Kim WK, Suh C. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006; 37: 1037-42.KimHSohnH-JKimSLeeJSKimWKSuhCEarly lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myelomaBone Marrow Transplant20063710374210.1038/sj.bmt.1705373Search in Google Scholar
Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Franke N, Winter A, et al. Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant. Leuk Lymphoma 2015; 56: 2668-73.Jimenez-ZepedaVHReeceDETrudelSChenCFrankeNWinterAAbsolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplantLeuk Lymphoma20155626687310.3109/10428194.2014.1003057Search in Google Scholar
Oleinika K, Nibbs RJ, Graham GJ, Fraser AR. Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol 2013; 171: 36-45.OleinikaKNibbsRJGrahamGJFraserARSuppression, subversion and escape: the role of regulatory T cells in cancer progressionClin Exp Immunol2013171364510.1111/j.1365-2249.2012.04657.xSearch in Google Scholar
Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, Chaput N, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005; 202: 1075-85.GhiringhelliFMénardCTermeMFlamentCTaiebJChaputNCD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent mannerJ Exp Med200520210758510.1084/jem.20051511Search in Google Scholar
Joshua DE, Brown RD, Ho PJ, Gibson J. Regulatory T cells and multiple myeloma. Clin Lymphoma Myeloma 2008; 8: 283-6.JoshuaDEBrownRDHoPJGibsonJRegulatory T cells and multiple myelomaClin Lymphoma Myeloma20088283610.3816/CLM.2008.n.039Search in Google Scholar
Dosani T, Carlsten M, Maric I, Landgren O. The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma and their uses in immunotherapies. Blood Cancer J 2015; 5: e321.DosaniTCarlstenMMaricILandgrenOThe cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma and their uses in immunotherapiesBlood Cancer J20155e32110.1038/bcj.2015.49Search in Google Scholar
Sharabi A, Haran-Ghera N. Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy. Bone Marrow Res 2011; 2011 : 269519.SharabiAHaran-GheraNImmune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapyBone Marrow Res2011201126951910.1155/2011/269519Search in Google Scholar
Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117: 4691-5.RajkumarSVHarousseauJLDurieBAndersonKCDimopoulosMKyleRConsensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood20111174691510.1182/blood-2010-10-299487Search in Google Scholar
Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza F, et al. Proposed definition of “poor mobilizer” in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2012; 47: 342-351.OlivieriAMarchettiMLemoliRTarellaCIaconeALanzaFProposed definition of “poor mobilizer” in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo OsseoBone Marrow Transplant20124734235110.1038/bmt.2011.82Search in Google Scholar
Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Fra. Blood 2002; 99: 731-5.MoreauPFaconTAttalMHulinCMichalletMMaloiselFComparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe FraBlood200299731510.1182/blood.V99.3.731Search in Google Scholar
Porrata LF, Markovic SN. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clin Exp Med 2004; 4: 78-85.PorrataLFMarkovicSNTimely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantationClin Exp Med20044788510.1007/s10238-004-0041-4Search in Google Scholar
Lee SE, Yahng SA, Cho BS, Eom KS, Kim YJ, Kim HJ, et al. Lymphocyte subset analysis for the assessment of treatment-related complications after autologous stem cell transplantation in multiple myeloma. Cytotherapy 2012; 14: 505-12.LeeSEYahngSAChoBSEomKSKimYJKimHJLymphocyte subset analysis for the assessment of treatment-related complications after autologous stem cell transplantation in multiple myelomaCytotherapy2012145051210.3109/14653249.2012.655421Search in Google Scholar
Jost S, Altfeld M. Control of human viral infections by natural killer cells. Ann Rev Immunol 2013; 31: 163-94.JostSAltfeldMControl of human viral infections by natural killer cellsAnn Rev Immunol2013311639410.1146/annurev-immunol-032712-100001Search in Google Scholar
Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, et al. Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology 2013; 2: e26494.SemeraroMVacchelliEEggermontAGalonJZitvogelLKroemerGTrial Watch: Lenalidomide-based immunochemotherapyOncoimmunology20132e2649410.4161/onci.26494Search in Google Scholar
Lagrue K, Carisey A, Morgan DJ, Chopra R, Davis DM. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood 2015; 126: 50-60.LagrueKCariseyAMorganDJChopraRDavisDMLenalidomide augments actin remodeling and lowers NK-cell activation thresholdsBlood2015126506010.1182/blood-2015-01-625004Search in Google Scholar
Attal M, Lauwers-Cances V, Meril G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782-91.AttalMLauwers-CancesVMerilGCaillotDMoreauPFaconTLenalidomide maintenance after stem-cell transplantation for multiple myelomaN Engl J Med201236617829110.1056/NEJMoa1114138Search in Google Scholar
Adeegbe D, Serafini P, Bronte V, Zoso A, Ricordi C, Inverardi L. In vivo induction of myeloid suppressor cells and CD4(+)Foxp3(+) T regulatory cells prolongs skin allograft survival in mice. Cell Transplant 2011; 20: 941-54.AdeegbeDSerafiniPBronteVZosoARicordiCInverardiLIn vivo induction of myeloid suppressor cells and CD4(+)Foxp3(+) T regulatory cells prolongs skin allograft survival in miceCell Transplant2011209415410.3727/096368910X540621Search in Google Scholar
Rutella S, Zavala F, Danese S, Kared H, Leone G. Granulocyte Colony-Stimulating Factor: A Novel Mediator of T Cell Tolerance. J Immunol 2005; 175: 7085-91.RutellaSZavalaFDaneseSKaredHLeoneGGranulocyte Colony-Stimulating Factor: A Novel Mediator of T Cell ToleranceJ Immunol200517570859110.4049/jimmunol.175.11.7085Search in Google Scholar
Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado E, Jimenez-Zamudio L, Garcia-Latorre E, Moreno-Lafont M, et al. Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin’s lymphoma and multiple myeloma. Ann Hematol 2006; 85: 308-14.Vela-OjedaJGarcía-Ruiz EsparzaMAReyes-MaldonadoEJimenez-ZamudioLGarcia-LatorreEMoreno-LafontMPeripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin’s lymphoma and multiple myelomaAnn Hematol2006853081410.1007/s00277-006-0090-8Search in Google Scholar
Kobbe G, Bruns I, Fenk R, Czibere A, Haas R. Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. Bone Marrow Transplant 2009; 43: 669-77.KobbeGBrunsIFenkRCzibereAHaasRPegfilgrastim for PBSC mobilization and autologous haematopoietic SCTBone Marrow Transplant2009436697710.1038/bmt.2009.59Search in Google Scholar
Bruns I, Steidl U, Fischer JC, Czibere A, Kobbe G, Raschke S, et al. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica 2008; 93: 347-55.BrunsISteidlUFischerJCCzibereAKobbeGRaschkeSPegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factorHaematologica2008933475510.3324/haematol.12081Search in Google Scholar
Engelhardt M, Terpos E, Kleber M, Gay F, Wasch R, Morgan G, et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 2014; 99: 232-42.EngelhardtMTerposEKleberMGayFWaschRMorganGEuropean Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myelomaHaematologica2014992324210.3324/haematol.2013.099358Search in Google Scholar
Kopinska A, Krawczyk-Kulis M, Dziaczkowska-Suszek J, Bieszczad K, Jagoda K, Kyrcz-Krzemien S. The importance of the number of transplanted cells with dipeptidyl peptidase-4 expression on the haematopoietic recovery and lymphocyte reconstitution in patients with multiple myeloma after autologous haematopoietic stem-cell transplantation. Hematol Oncol 20 15; doi.10.1002/hon.2267.KopinskaAKrawczyk-KulisMDziaczkowska-SuszekJBieszczadKJagodaKKyrcz-KrzemienSThe importance of the number of transplanted cells with dipeptidyl peptidase-4 expression on the haematopoietic recovery and lymphocyte reconstitution in patients with multiple myeloma after autologous haematopoietic stem-cell transplantationHematol Oncol2015doi.10.1002/hon.2267Open DOISearch in Google Scholar
Batorov EV, Shevela EY, Tikhonova MA, Batorova DS, Ushakova GY, Sizikova SA, et al. Mesenchymal stromal cells improve early lymphocyte recovery and T cell reconstitution after autologous hematopoietic stem cell transplantation in patients with malignant lymphomas. Cell Immonol 2015; 297: 80-6.BatorovEVShevelaEYTikhonovaMABatorovaDSUshakovaGYSizikovaSAMesenchymal stromal cells improve early lymphocyte recovery and T cell reconstitution after autologous hematopoietic stem cell transplantation in patients with malignant lymphomasCell Immonol201529780610.1016/j.cellimm.2015.07.001Search in Google Scholar
